FIBROGEN INC - COMMON

FibroGen to Report Third Quarter 2021 Financial Results

26 Oct 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

25 Oct 2021 04:00:01 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

25 Aug 2021 04:00:00 By Nasdaq GlobeNewswire

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

19 Aug 2021 16:35:00 By Nasdaq GlobeNewswire

FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

16 Aug 2021 04:00:01 By Nasdaq GlobeNewswire

FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

11 Aug 2021 04:00:01 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2021 Financial Results

09 Aug 2021 13:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2021 Financial Results

29 Jul 2021 04:00:01 By Nasdaq GlobeNewswire

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

19 Jul 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

15 Jul 2021 15:26:31 By Nasdaq GlobeNewswire

FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

12 Jul 2021 04:00:00 By Nasdaq GlobeNewswire

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

25 Jun 2021 06:15:00 By Nasdaq GlobeNewswire

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

17 Jun 2021 04:00:00 By Nasdaq GlobeNewswire

Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

16 Jun 2021 05:00:01 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

27 May 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2021 Financial Results

10 May 2021 13:01:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2021 Financial Results

03 May 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conference

28 Apr 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 Apr 2021 04:00:00 By Nasdaq GlobeNewswire

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 Apr 2021 04:00:01 By Nasdaq GlobeNewswire